Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.
Trněný M, Avigdor A, McKinney MS, Paneesha S, Wahlin BE, Hrom JS, Cunningham D, Morley N, Canales M, Bastos-Oreiro M, Belada D, Devizzi L, Zheng F, DeMarini DJ, Jiang W, Jiang P, Lynch RC.
Trněný M, et al. Among authors: jiang p, jiang w.
EClinicalMedicine. 2023 Aug 18;63:102130. doi: 10.1016/j.eclinm.2023.102130. eCollection 2023 Sep.
EClinicalMedicine. 2023.
PMID: 37662520
Free PMC article.